Cigna earnings beat by $0.04, revenue topped estimates
On Tuesday, JMP Securities reaffirmed their optimistic stance on DBV Technologies S.A (NASDAQ:DBVT), maintaining a Market Outperform rating and a $10.00 price target, well below the analyst high target of $33.94. The firm’s analyst highlighted the unmet need in the market for an effective peanut allergy treatment for children, noting that DBV Technologies’ Viaskin Peanut is gaining traction among doctors due to its safety profile and ease of use. The current market valuation of DBV Technologies, at approximately $80 million, reflects its capital requirements to bring Viaskin Peanut to market, according to the analyst. InvestingPro analysis suggests the stock may be undervalued based on its Fair Value calculations.
The analyst reflected on the past, recalling that in 2017, DBV Technologies and Aimmune had a combined valuation of over $3 billion, based on the potential of their respective peanut allergy treatments. However, the landscape has changed, with limited use of Aimmune’s Palforzia and allergists often preferring in-office oral immunotherapy, which can be stressful and logistically challenging for families. Additionally, while Xolair has been effective for some patients, concerns over needle phobia and cost have been raised. According to InvestingPro data, DBV Technologies maintains a strong financial position with more cash than debt and a healthy current ratio of 2.22, though it’s currently burning through cash rapidly.
Viaskin Peanut stands out as it has been well-received by the medical community for its non-invasive administration and the progressive immune response modulation it offers to children. The anticipation is building for the upcoming results from the VITESSE trial in the fourth quarter of 2025, which is seen as the last major obstacle for Viaskin Peanut. The trial has been carefully designed to maximize the likelihood of success.
The commencement of the COMFORT safety studies is imminent, which will provide clearer timelines for the Biologics License Application (BLA) submissions. The analyst expressed confidence in the eventual approval and success of Viaskin Peanut within the allergist community, suggesting a positive outlook for DBV Technologies’ future.
In other recent news, DBV Technologies S.A. reported significant developments concerning its ongoing research and executive management. The company maintained its Market Outperform rating and a $10 price target from JMP Securities, with analysts highlighting the upcoming presentation of final efficacy data from its Phase 3 PEOPLE study. This study focuses on the long-term impact of Viaskin Peanut on children with peanut allergies. The data indicates a notable increase in the percentage of children completing the double-blind, placebo-controlled food challenge without reaching the stopping criteria, rising from 53% in the third year to 73% in the fourth year. Additionally, the number of patients able to raise their eliciting dose to approximately 3-4 peanuts increased from 48.3% to 66.7%, suggesting improved tolerance.
Moreover, DBV Technologies has amended the employment agreements for Chief Medical (TASE:BLWV) Officer Pharis Mohideen and Chief Financial Officer Virginie Boucinha to enhance severance benefits in the event of a change in control. These amendments, approved by the Board of Directors, are designed to ensure stability and recognize the executives’ commitment. Mohideen could receive a lump sum equal to two years of his base salary plus his target annual bonus, while Boucinha’s agreement includes a severance indemnity equal to 12 months of gross remuneration under similar circumstances. The specifics of these agreements were detailed in a recent SEC filing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.